MLN2480 is an orally bioavailable pan-Raf kinase inhibitor that inhibits MAP kinase pathway signaling in BRAF-mutant melanoma models. It shows antitumor activity in melanoma, colon, lung, and pancreatic cancer xenograft models. MLN2480 demonstrates synergistic activity with TAK-733, an allosteric MEK kinase inhibitor.
